Angiotensin Converting Enzyme Inhibitor-Related Angioedema: Onset, Presentation, and Management

Annals of Otology, Rhinology and Laryngology

Volumn 124, Issue 2, 2015, Pages 89-96

  Chan, Norman J ^a   Soliman, Ahmed M S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; airway intervention; angioedema; intubation

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LISINOPRIL; QUINAPRIL; RAMIPRIL; ANTIALLERGIC AGENT;

ADULT; AGED; ANGIONEUROTIC EDEMA; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG USE; DYSPHAGIA; DYSPNEA; FACE; HUMAN; HYPERTENSION; INTUBATION; LARYNGOSCOPY; LARYNX; LARYNX EDEMA; LENGTH OF STAY; LIP; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MOUTH; PRIORITY JOURNAL; REVIEW; SOFT PALATE; TONGUE; TRACHEOTOMY; TREATMENT DURATION; VOICE CHANGE; ANGIOEDEMA; CHEMICALLY INDUCED; CLASSIFICATION; COMPLICATION; EAR NOSE THROAT SURGERY; ENDOTRACHEAL INTUBATION; FEMALE; HOSPITAL; LARYNGEAL EDEMA; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RESPIRATION CONTROL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TIME; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AIRWAY MANAGEMENT; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ALLERGIC AGENTS; FEMALE; HOSPITALS, URBAN; HUMANS; INTUBATION, INTRATRACHEAL; LARYNGEAL EDEMA; LARYNGOSCOPY; MALE; MIDDLE AGED; OTORHINOLARYNGOLOGIC SURGICAL PROCEDURES; PENNSYLVANIA; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84925286977     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003489414543069     Document Type: Review

References (28)

1. Bickett DP,. Using ACE inhibitors appropriately. Am Fam Physician. 2002; 66: 461-468.
2. Winters ME, Rosenbaum S, Vilke GM, Almazroua FY,. Emergency department management of patients with ACE-inhibitor angioedema. J Emerg Med. 2013; 45: 775-780.
3. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008; 100: 327-332.
4. Iyer VN, Lim KG,. Chronic cough: an update. Mayo Clin Proc. 2013; 88: 1115-1126.
5. Al-Khudari S, Loochtan MJ, Peterson E, Yaremchuk KL,. Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2011; 121: 2327-2334.
6. Grant NN, Deeb ZE, Chia SH,. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg. 2007; 137: 931-935.
7. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005; 165: 1637-1642.
8. Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008; 51: 1624-1630.
9. Pare G, Kubo M, Byrd JB, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013; 23: 470-478.
10. Piller LB, Ford CE, Davis BR, et al. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2006; 8: 649-656.
11. Tai S, Mascaro M, Goldstein NA,. Angioedema: a review of 367 episodes presenting to three tertiary care hospitals. Ann Otol Rhinol Laryngol. 2010; 119: 836-841.
12. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010; 20: 532-536.
13. Mahoney EJ, Devaiah AK,. Angioedema and angiotensin-converting enzyme inhibitors: are demographics a risk? Otolaryngol Head Neck Surg. 2008; 139: 105-108.
14. Warner KK, Viscontin JA, Tschampel MM,. Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema. Ann Pharmacother. 2000; 34: 526-528.
15. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008; 51: 141-147.
16. Norman JL, Holmes WL, Bell WA, Finks SW,. Life-threatening ACE inhibitor-induced angioedema after eleven years on lisinopril. J Pharm Pract. 2013; 26: 382-388.
17. Patterson SM, Hughes C, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012; 5: CD008165.
18. Ishoo E, Shah UK, Grillone GA, et al. Predicting airway risk in angioedema: staging system based on presentation. Otolaryngol Head Neck Surg. 1999; 121: 263-268.
19. McCormick M, Folbe AJ, Lin HS, et al. Site involvement as a predictor of airway intervention in angioedema. Laryngoscope. 2011; 121: 262-266.
20. Maslan J, Mims JW,. What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin North Am. 2014; 47: 13-22.
21. Hong X, Wang X,. Early life precursors, epigenetics, and the development of food allergy. Semin Immunopathol. 2012; 34: 655-669.
22. Mims JW,. Allergic rhinitis. Facial Plast Surg Clin N Am. 2012; 20: 11-20.
23. Silverberg JI, Hanifin JM,. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013; 132: 1132-1138.
24. US Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States., 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed December 21, 2013.
25. Lin RY, Levine RJ, Lin H,. Adverse drug effects and angioedema hospitalizations in the United States from 2000 to 2009. Allergy Asthma Proc. 2013; 34: 65-71.
26. Beavers CJ, Dunn SP, Macaulay TE,. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother. 2011; 45: 520-524.
27. Cole SW, Lundquist LM,. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother. 2013; 47: 49-55.
28. Sheffer AL, MacGinnitie AJ, Campion M, et al. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013; 110: 184-188.